AAIC 2024

Cogstate Scientific Involvement, Meeting Opportunities, and Remote Cognitive Testing.

Cogstate is honored to be a part of the program at the 2024 Alzheimer’s Association International Conference (AAIC) in Philadelphia. The sharing of knowledge at these pivotal events is vital to help advance dementia science to better support the millions of individuals, families, and communities impacted by Alzheimer’s disease.

We invite those attending the conference to come to our scientific presentations, stop by our booth, and/or reach out to book a meeting with our team! For those who can’t make it in-person, please don’t hesitate to reach out to learn more about our services or book a meeting outside of AAIC.

Meet with Cogstate at AAIC | Try Remote Cognitive Testing

Cogstate’s team will be available during the duration of the event for meetings, coffee discussions, or quick chats. Whatever suits your schedule!

Stop By Booth #1407

Be sure to swing by Cogstate’s booth to chat, to grab a fun promo item, and to demo some of our digital cognitive assessments that have been optimized for remote and self-administration. Our team will be available to discuss both traditional and decentralized clinical trial services for CNS-related studies.

Book a Meeting

We’d like to meet with you during the event. Cogstate has arranged a business suite on the exhibit floor just steps away from the presentations and posters. Please reach out to your Cogstate contacts to book a meeting during the event or submit this form and our team will reach out to make arrangements.

Cogstate Scientific Presentations at AAIC

For over 20 years, Cogstate has proudly supported the leading-edge research needs of biopharmaceutical companies and academic institutions, and the clinical care needs of physicians and patients around the world, with particular emphasis and experience in Alzheimer’s Disease. At this year’s AAIC event, our expertise and technology are part of 22 presentations.

Presentations

TitleFormatDate/Time
Association of basal forebrain atrophy with cognitive decline in early Alzheimer's diseasePosterSaturday, July 27, 2024
Developing a machine learning stack model to forecast the progression of mild cognitive impairment to Alzheimer's dementia, using the Australian Imaging, Biomarker & Lifestyle (AIBL) Study datasetPosterSaturday, July 27, 2024
Cross-cohort epigenome-wide association study in Alzheimer's disease risk and related traitsOral SessionSaturday, July 27, 2024: 8:35 AM – 9:50 AM EDT
Associations between BDNF Val66Met and tau-PET and episodic memory performance in sporadic ADPosterSaturday, July 27, 2024: 1:00 PM – 1:35 PM EDT
Early identification of participants at risk of cognitive decline: An online tool for patient prediction of cognitive declinePosterSaturday, July 27, 2024
Harmonization of data from neuropsychological tests used in different prospective studies- Descending a Tower of BabelPosterSunday, July 28, 2024
Data-driven Cognitive Composites and APOE ε4 Carriage Predict Progression to Mild Cognitive Impairment in Cognitively Unimpaired Older AdultsPosterSunday, July 28, 2024
Associations between BDNF Val66Met and tau-PET and episodic memory performance in sporadic ADPosterSunday, July 28, 2024
Association between anxiety, stress, and cognition in middle-aged adults: Exploratory factor analysis across multiple anxiety and stress measuresPosterSunday, July 28, 2024
Developing a machine learning stack model to forecast the progression of mild cognitive impairment to Alzheimer’s dementia, using the Australian Imaging, Biomarker & Lifestyle (AIBL) Study datasetPosterSunday, July 28, 2024
Early identification of participants at risk of cognitive decline: An online tool for patient prediction of cognitive decline.Featured Research SessionSunday, July 28, 2024: 2:00 PM – 3:30 PM EDT, 204 ABC
Development of Xanamem, an isoform 1 specific inhibitor of 11-βHSD, as a procognitive and disease modifying treatment for mild/moderate Alzheimer’s disease. A pharmacodynamic and biomarker driven approach.PosterMonday, July 29, 2024
Baseline demographic, risk and cognitive characteristics of the final randomized sample enrolled in a decentralised multi-domain lifestyle intervention trial (BetterBrains) to delay cognitive declinePosterMonday, July 29, 2024
Cross-cohort epigenome-wide association study in Alzheimer’s disease risk and related traits.PosterTuesday, July 30, 2024
Acceptability and validity of the smartphone-administered version of the Cogstate Brief Battery in middle-aged and older adults of the Healthy Brain ProjectPosterTuesday, July 30, 2024
OML-Combine: Online Machine Learning tool for Combining datasets to increase power and facilitate multi-centre collaboration on Alzheimer's disease studiesPosterWednesday, July 31, 2024
Update on the current state of speech and language testing in Alzheimer's DiseasePosterWednesday, July 31, 2024
Association of basal forebrain atrophy with cognitive decline in early Alzheimer’s diseasePosterWednesday, July 31, 2024
Acceptability and validity of a smartphone-administered word list learning test, LILA, in cognitively unimpaired adultsPosterWednesday, July 31, 2024
Exploring how genetic variation within Aquaporin-4, influences the relationship between sleep and amyloid betaPosterWednesday, July 31, 2024
Rethinking the residual approach for estimating cognitive resilience and resistance to AD pathologyPosterWednesday, July 31, 2024
Learning deficits in late middle-aged APOE ε4 carriers: Implications for emergent Alzheimer’s diseaseFeatured Research SessionThursday, August 1, 2024: 10:00 AM – 11:30 AM EDT

View the full AAIC 2024 conference program here

How can we help you optimize the measurement of brain health?

Contact Our Team
Cogstate
© 2024 Cogstate Ltd.

Cogstate acknowledges Aboriginal and Torres Strait Islander people as the Traditional Custodians of the lands where many of our team members live and work. We pay respect to their Elders past and present.